Log in

NYSEAMERICAN:OGENOragenics Stock Price, Forecast & News

$0.61
+0.02 (+3.41 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.56
Now: $0.61
$0.62
50-Day Range N/A
52-Week Range
$0.35
Now: $0.61
$0.88
Volume1.67 million shs
Average Volume2.23 million shs
Market Capitalization$33.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone+1-813-2867900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$33.57 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Oragenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Oragenics.

How were Oragenics' earnings last quarter?

Oragenics Inc (NYSEAMERICAN:OGEN) issued its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.03. View Oragenics' earnings history.

When did Oragenics' stock split? How did Oragenics' stock split work?

Shares of Oragenics reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for OGEN?

1 brokers have issued twelve-month price targets for Oragenics' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Oragenics' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 229.8% from the stock's current price. View analysts' price targets for Oragenics.

Has Oragenics been receiving favorable news coverage?

News coverage about OGEN stock has been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oragenics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutOragenics.

Are investors shorting Oragenics?

Oragenics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,110,000 shares, a drop of 36.6% from the April 30th total of 1,750,000 shares. Based on an average daily volume of 2,240,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.8% of the company's stock are short sold. View Oragenics' Current Options Chain.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

Who are Oragenics' major shareholders?

Oragenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Third Security LLC (10.00%). Company insiders that own Oragenics stock include Family Lp Koski and Robert C Koski. View institutional ownership trends for Oragenics.

Which institutional investors are buying Oragenics stock?

OGEN stock was acquired by a variety of institutional investors in the last quarter, including Third Security LLC. View insider buying and selling activity for Oragenics.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.61.

How big of a company is Oragenics?

Oragenics has a market capitalization of $33.57 million. Oragenics employs 6 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.